Experienced in Polymorphous Low Grade Adenocarcinoma

Dr. Douglas F. Ciuba

Radiation Oncology
Radiation Oncology Of Columbus PC
1831 5th Ave, 
Columbus, GA 
 (640.6 mi)
Accepting New Patients
Offers Telehealth
Experienced in Polymorphous Low Grade Adenocarcinoma
Radiation Oncology Of Columbus PC
1831 5th Ave, 
Columbus, GA 
 (640.6 mi)
OverviewInsuranceLocationsClinical Research

Overview

Douglas Ciuba is a Radiation Oncologist in Columbus, Georgia. Dr. Ciuba and is rated as an Experienced provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Lung Cancer, Pleuropulmonary Blastoma, and Familial Prostate Cancer. Dr. Ciuba is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in GA
Hospital Affiliations
St Francis Hospital- Emory Healthcare
Piedmont Columbus Regional Midtown
Emory University Hospital Midtown
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Friday Health
  •  Alliant Health
  •  CareSource
  •  UnitedHealthcare
View 1 More Insurance +

Locations

RADIATION ONCOLOGY OF COLUMBUS PC
1831 5th Ave, Columbus, GA 31904

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Radiation
Study Phase: Phase 3
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)
GRECO-1: Phase I/II, Randomized, Placebo-Controlled Study of Stereotactic Body Radiation Therapy (SBRT) and GC4711 for Centrally Located or Large, Node-Negative Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: April 30, 2024
Intervention Type: Drug
Study Drug: GC4711
Study Phase: Phase 1/Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer
A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer
Enrollment Status: Terminated
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Clonidine HCl Mucoadhesive Buccal Tablet
Study Phase: Phase 2/Phase 3
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer
Enrollment Status: Terminated
Publish Date: March 23, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 2
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects
Enrollment Status: Terminated
Publish Date: July 22, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
View 5 Less Clinical Trials

1 Total Publications

Updated feasibility and reproducibility results of multi-institutional study of noninvasive breast tumor bed boost.
Updated feasibility and reproducibility results of multi-institutional study of noninvasive breast tumor bed boost.
Journal: Brachytherapy
Published: April 16, 2016
Similar Doctors
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. William J. Mcafee
Radiology | Radiation Oncology
Experienced in Polymorphous Low Grade Adenocarcinoma
Dr. William J. Mcafee
Radiology | Radiation Oncology

Phoebe Putney Memorial Hospital, Inc.

126 Hwy 280 W, 
Americus, GA 
 (51.4 mi)
229-924-6100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Mcafee is a Radiologist and a Radiation Oncologist in Americus, Georgia. Dr. Mcafee and is rated as a Distinguished provider by MediFind in the treatment of Polymorphous Low Grade Adenocarcinoma. His top areas of expertise are Familial Prostate Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Endometrial Cancer. Dr. Mcafee is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile